What is the key difference between psilocybin and SSRI antidepressants in their brain action?

While SSRIs broadly increase serotonin transmission non-specifically across various receptors, psilocybin primarily and selectively binds to and activates the serotonin 2A receptor. This selectivity is thought to explain its specific effects and therapeutic potential compared to SSRIs.

What role does the serotonin 2A receptor play in psilocybin's effects?

The serotonin 2A receptor is crucial because it's highly expressed in brain areas like the prefrontal and visual cortex. Psilocybin's strong and selective binding to this receptor triggers specific changes in neural circuitry, increasing lateral communication and reducing hierarchical organization across brain regions, leading to profound perceptual and emotional alterations.

What are the legal implications and safety guidelines for psilocybin use?

As of May 2023, psilocybin is a Schedule I drug in the United States, meaning it is largely illegal, with exceptions for therapeutic use in Oregon and decriminalized areas like Oakland, California. Safety guidelines emphasize use in controlled settings with guides, avoiding use by individuals under 25, those with a predisposition to psychosis or bipolar disorder, or those on antidepressants.

How are psilocybin mushroom dosages translated to milligrams for clinical use?

Typically, 1 gram of psilocybin mushrooms contains approximately 10 milligrams of psilocybin, assuming a 1% concentration. Clinical studies often use synthetic psilocybin in doses of 10mg (familiarization), or 25-30mg (therapeutic macro dose), while 'heroic doses' in informal settings might equate to 50mg (about 5 grams of mushrooms).

What constitutes an ideal therapeutic 'set and setting' for a psilocybin journey?

An ideal set and setting involve a safe, controlled environment, typically a single room, with one or two individuals acting as guides. The person taking psilocybin should ideally be lying down with an eye mask to facilitate introspection. Music, carefully curated to match the journey's emotional contour, is also a critical component.

How does psilocybin affect one's perception and emotional response to music?

Studies show that psilocybin can rewire connections between emotion centers and auditory perception networks. After a psilocybin session, people often report a return of elevated emotionality and joy from music they liked, and a diminished capacity for sad music to induce depression, which is linked to measurable brain activation changes.

What is the primary mechanism of neuroplasticity induced by psilocybin, and is it neurogenesis?

The predominant theory is that psilocybin induces neuroplasticity primarily through the addition and strengthening of new neural connections, specifically the growth of new dendritic spines on pyramidal neurons in the frontal cortex, and an expansion of functional connectivity across brain networks. Neurogenesis (production of new neurons) is not considered the main mode of plasticity in adult humans by most neuroscientists.

What role do concepts like 'oceanic boundlessness' and 'ego dissolution' play in therapeutic outcomes?

Experiences of 'oceanic boundlessness' (a mystical, interconnected feeling) and 'ego dissolution' (loss and regaining of self-sense) are positively correlated with therapeutic outcomes, particularly for depression. While anxiety can be part of the peak experience during ego dissolution and 'letting go' is encouraged, excessively high anxiety levels are inversely correlated with positive long-term results.

How effective is psilocybin-assisted therapy for major depression compared to traditional treatments?

Recent clinical trials show psilocybin-assisted therapy, especially with 25-30mg doses and psychological support, produces large, rapid, and sustained antidepressant effects. The effect sizes are reported to be approximately 2.5 times greater than psychotherapy alone and more than four times greater than typical antidepressant drug treatments, with 60-75% of participants experiencing substantial relief.

What specific conditions show the strongest evidence for psilocybin's therapeutic use?

The strongest evidence for positive therapeutic outcomes with psilocybin, administered under controlled conditions, is for cancer-related depression, cancer-related anxiety, and treatment-resistant depression. Moderate evidence exists for alcohol use disorder and tobacco addiction, while minimal evidence supports its use for OCD, cluster headaches, migraines, and demoralization from AIDS diagnoses.

How can anxiety during a psilocybin session be managed in real-time?

Preliminary and unpublished data suggest that breathing tools, specifically the physiological sigh, can effectively reduce anxiety in real-time during a psychedelic session. Guides can teach this technique beforehand, allowing individuals to self-direct their calm and move through challenging peaks of anxiety.

Key Moments

How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks

Andrew Huberman

Science & Technology3 min read130 min video

May 8, 2023|2,789,137 views|57,930|5,678

andrew huberman huberman lab podcast huberman podcast dr. andrew huberman neuroscience huberman lab andrew huberman podcast the huberman lab podcast science podcast psilocybin psychedelics

Save to Pod

Key Moments

TL;DR

Psilocybin rewires the brain by targeting serotonin receptors, promoting neuroplasticity for treating depression and addiction.

Key Insights

Psilocybin primarily acts by mimicking serotonin and strongly activating the serotonin 2A receptor, which is key to its therapeutic effects.

The therapeutic benefits of psilocybin are linked to its ability to induce neuroplasticity, making the brain more interconnected and less rigidly structured.

A positive psilocybin experience, often characterized by 'oceanic boundlessness' and 'ego dissolution', is strongly correlated with therapeutic success.

The 'set' (mindset) and 'setting' (environment and guides) are critical for ensuring a safe and therapeutically beneficial psilocybin journey.

Psilocybin can lead to long-lasting positive changes in mood, creativity, and emotional responses, particularly evident in its effectiveness for depression and addiction.

While psilocybin induces neuroplasticity, this rewiring is adaptive, primarily occurring through the strengthening or elimination of neural connections, not through neurogenesis.

THE NEUROBIOLOGY OF PSILOCYBIN

Psilocybin, found in 'magic mushrooms', is chemically similar to serotonin and primarily exerts its effects by strongly activating the serotonin 2A receptor. This specific interaction is crucial, differentiating its effects from non-specific serotonin reuptake inhibitors (SSRIs) often used for depression. The activation of serotonin 2A receptors, particularly in the neocortex, triggers significant neuroplasticity, altering brain circuitry involved in perception, cognition, and emotion for potentially long-lasting changes.

NEUROPLASTICITY AND BRAIN REWIRING

Psilocybin induces neuroplasticity by increasing communication and integration between previously disparate brain regions, reducing the brain's modularity and hierarchical organization. Instead of 'training' specific pathways, it broadens neural connectivity. This rewiring is believed to occur mainly through the growth and strengthening of new neural connections, particularly dendritic spines on neurons, which can persist long after the drug's immediate effects wear off.

SET AND SETTING: KEYS TO A THERAPEUTIC JOURNEY

The 'set' (mindset of the individual) and 'setting' (environment, guides, music) are paramount for a safe and effective psilocybin experience. A controlled, safe setting with supportive, sober guides is essential. Factors like maintaining eyes closed (using an eye mask) and the strategic use of music, which can profoundly influence the emotional and perceptual experience, are critical components in guiding the journey towards therapeutic outcomes.

DOSING AND THE PSYCHEDELIC EXPERIENCE

Dosage is critical, with clinical studies typically using synthetic psilocybin ranging from 10-30 milligrams. While microdosing (1-3 mg) is discussed, higher doses are generally associated with more significant therapeutic benefits. The subjective experience, often lasting 4-6 hours, can involve intense emotions, perceptual distortions, and 'ego dissolution'. The duration and intensity are influenced by dose and individual metabolism, highlighting the need for careful consideration of dosage in therapeutic contexts.

THERAPEUTIC APPLICATIONS AND CLINICAL EVIDENCE

Emerging clinical evidence strongly supports the use of psilocybin for treating treatment-resistant depression, with studies showing significant and sustained relief. It also shows promise for alcohol and tobacco addiction, anxiety related to terminal illness, OCD, and cluster headaches. The efficacy appears to be linked to the quality of the acute psychedelic experience, where feelings of unity, spirituality, and insight correlate with positive therapeutic outcomes.

SAFETY CONSIDERATIONS AND CONTRAINDICATIONS

Psilocybin is a powerful substance and its use is not suitable for everyone. Individuals with a predisposition to psychosis, bipolar disorder, or who are pregnant or breastfeeding should avoid it. The brain's ongoing development in individuals 25 and younger also necessitates caution. Furthermore, potential interactions with antidepressants require careful medical consultation. While generally safe when administered in controlled clinical settings with proper guidance, understanding these risks is crucial.

Mentioned in This Episode

●Supplements

●Companies

●Organizations

●Books

●People Referenced

Common Questions

Psilocybin is a psychedelic tryptamine that closely resembles serotonin. Its main effect is to mimic serotonin by strongly activating a subset of serotonin 2A receptors, particularly in the neocortex and visual cortex, leading to neuroplasticity and altered consciousness.

Topics

Psychedelics Neuroscience & the Brain Mental Health & Psychology Depression Treatment Medicine & Clinical Brain Connectivity Serotonin Receptors Mind-altering Substances Addiction Therapy

Mentioned in this video

Drugs & Medications

LSD

Another psychedelic mentioned, noting that today's episode will focus specifically on psilocybin.

MDMA

Mentioned as a psychedelic in the general sense, but not a classic psychedelic. It was later compared to psilocybin in a study about brain connectivity.

Ketamine

A non-classical psychedelic mentioned for future discussion on the podcast.

Zoloft

An SSRI (Selective Serotonin Reuptake Inhibitor) mentioned as a standard antidepressant treatment, often associated with side effects.

mescaline

A psychedelic mentioned for future discussion on the podcast.

Psilocin

The active compound that psilocybin is converted into in the body, responsible for the changes in consciousness and neural rewiring effects.

5-MeO-DMT

Another tryptamine psychedelic mentioned alongside DMT and psilocybin.

Prozac

An SSRI (Selective Serotonin Reuptake Inhibitor) mentioned as a standard antidepressant treatment, contrasted with psilocybin's more targeted action.

Ayahuasca

A classic psychedelic discussed by Dr. Robin Carhart-Harris in his upcoming episode on the Huberman Lab podcast.

People

Rick Rubin

A highly creative music producer who appeared on the Huberman Lab podcast to discuss the creative process.

Roland Griffiths

A researcher pioneering legal and research efforts in defining clinical data for psilocybin.

David Spiegel

A doctor at Stanford School of Medicine whose laboratory collaborated with Huberman Lab on research showing the physiological sigh reduces anxiety.

Nolan Williams

A researcher pioneering legal and research efforts in defining clinical data for psilocybin.

Matthew Johnson

A researcher from Johns Hopkins running psychedelic trials, who discussed the importance of 'letting go' during a psilocybin journey and has started incorporating physiological sighs.

Andrew Huberman

Host of the Huberman Lab podcast and a professor of neurobiology and ophthalmology at Stanford School of Medicine.

Robin Carhart-Harris

Professor at University of California San Francisco and a major pioneer in psychedelic studies, who emphasized the critical role of music in therapeutic journeys.

Supplements

Momentous Supplements

A partner of the Huberman Lab podcast that offers supplements for various benefits, including sleep, focus, and hormone augmentation.

DMT

Another tryptamine psychedelic mentioned in comparison to psilocybin.

HVMN Ketone-IQ

A ketone supplement that increases blood ketones to improve cognition and physical performance, even for those not on a ketogenic diet.

Organizations

Stanford School of Medicine

Academic and research institution where Andrew Huberman is a professor.

FDA

The Food and Drug Administration, which granted psilocybin breakthrough status, accelerating research into its therapeutic potential.

UCSF

University of California San Francisco, where Robin Carhart-Harris conducts research on psychedelics.

Brian Roth's Lab at Duke

A research laboratory that published a review titled 'The Neural Basis of Psychedelic Action,' providing insights into brain networks activated during psychedelic journeys.

Companies

Eight Sleep

A sponsor that makes smart mattress covers with cooling, heating, and sleep tracking capacity to optimize sleep temperature.

Athletic Greens

A vitamin, mineral, and probiotic drink that covers foundational nutritional needs, focusing on gut health with probiotics and adaptogens.

ROKA

A sponsor that manufactures high-quality eyeglasses and sunglasses designed for clarity in various conditions, originally for sport but now with diverse aesthetics.

LMNT

An electrolyte drink with sodium, magnesium, and potassium, designed to support cognitive and physical performance by maintaining proper hydration and electrolyte balance.

Studies & Research

Johns Hopkins

University where Dr. Matthew Johnson conducts research on psychedelics and their therapeutic roles.

New England Journal of Medicine

A prominent journal that published studies on single-dose psilocybin for treatment-resistant depression in 2021 and November 2022.

Books

Journal of the American Medical Association Psychiatry

A journal that recently published clinical studies on psilocybin in 2021.

Cell Reports Medicine

The journal where Huberman Lab published collaborative work with Dr. David Spiegel's laboratory on the physiological sigh.

Legislation & Policy

Schedule I drug

The current legal classification of psilocybin in the United States as of May 2023, indicating it's considered to have a high potential for abuse and no accepted medical use.

Controlled Substances Act

Legislation invoked in the late 1960s and early 1970s that made psychedelics like psilocybin illegal in the United States.

Concepts

Serotonin

A neuromodulator naturally made by the brain and body; psilocybin's active form, psilocin, closely resembles and mimics serotonin, primarily by activating the 5-HT2A receptor.

Locations

Oakland, California

An area in the United States where psilocybin has been decriminalized.

Oregon

The state where psilocybin has been decriminalized and approved for use in particular therapeutic settings for depression and addiction, as of May 2023.